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Sun-protected human skin was maintained in organ
culture and treated with all-trans retinoic acid in the
presence or absence of reversible or irreversible
pharmacologic antagonists of c-erbB receptor tyro-
sine kinase activity. In the absence of these inhibi-
tors, all-trans retinoic acid induced epidermal
hyperplasia comparable to that induced in intact skin
by all-trans retinol or all-trans retinoic acid itself.
There was a strong correlation between inhibition of
epidermal hyperplasia in organ culture and inhibition
of epidermal-growth-factor-dependent keratinocyte
growth in monolayer culture. In additional studies
it was shown that all-trans retinoic acid could over-
come the known inhibitory effects of calcium on
expression of HB-EGF-like growth factor mRNA in
organ-cultured skin. Further, it was shown that an
antibody to HB-EGF-like growth factor inhibited
retinoid-stimulated epidermal hyperplasia in organ
culture and reduced proliferation in cultured kerati-
nocytes. In contrast, the c-erbB receptor tyrosine
kinase antagonists and the neutralizing HB-EGF-like
growth factor antibody were ineffective in inhibiting
all-trans-retinoic-acid-dependent survival and prolif-
eration of human dermal ®broblasts. Taken together,
these data indicate (i) that retinoid-induced epider-
mal hyperplasia in human skin proceeds through c-
erbB, and (ii) that HB-EGF-like growth factor is one
of the c-erbB ligands mediating this effect. Key
words: c-erbB/EGF-like growth factor/epidermal growth
factor receptor/heparin-binding/human skin organ culture/
retinoic acid. J Invest Dermatol 117:1335±1341, 2001
A
mong their many effects, biologically active retinoids
including all-trans retinoic acid (RA) and its precursor
all-trans retinol (ROL) exert substantial in¯uence over
the proliferation of many different cell types in
monolayer culture. The retinoid-responsive mechan-
ism(s) controlling cell growth are complex and multifaceted,
however. Some cells are stimulated to proliferate whereas others are
inhibited (Amos and Lotan, 1990; Rogers, 1997). Our own past
studies have shown that the same cells can be either stimulated or
inhibited, depending on the physiologic condition of the cells at the
time of treatment. For example, growth-inhibited human epider-
mal keratinocytes are stimulated to proliferate by RA whereas
rapidly proliferating keratinocytes are inhibited (Varani et al, 1989,
1991). These in vitro observations have in vivo counterparts: whereas
retinoid therapy inhibits epithelial proliferation in precancerous
actinic keratoses (Kligman et al, 1986) and in psoriatic lesions
(Goldfarb et al, 1988), RA stimulates keratinocyte growth and
epidermal thickening when applied topically to photodamaged skin
(Weiss et al, 1988; Fisher et al, 1991).
How retinoids regulate proliferation of keratinocytes and
other epithelial cells is not completely understood. Recent
studies have shown that retinoid treatment of intact human skin
and human skin in organ culture is associated with a rapid and
pronounced upregulation of heparin-binding EGF-like growth
factor (HB-EGF) mRNA, compared to untreated controls (Stoll
and Elder, 1998). Induction of HB-EGF has also been reported
in mice treated topically with RA (Xiao et al, 1999). HB-EGF,
as well as amphiregulin and transforming growth factor a
(TGF-a), interacts with multiple receptors of the c-erbB family,
of which the epidermal growth factor receptor (c-erbB-1) is the
prototype (Olayioye et al, 2000). In the aforementioned studies,
amphiregulin and TGF-a were not signi®cantly upregulated by
retinoid treatment. Interestingly, EGF itself appears not to be
expressed in the interfollicular epidermis (Elder et al, 1989).
In addition to retinoid effects on keratinocytes via the c-erbB
system, it is also important to consider the effects of topically
applied retinoids on all the resident and migratory cell types of
the skin. Studies from our laboratory have demonstrated that
retinoid-induced epidermal changes result, at least under some
conditions, from retinoid effects on dermal elements (Varani et
al, 1993b, 1994). Whether retinoid action in the stroma also
involves c-erbB activation is not known. As a way to address
these complex issues, in this study we have examined the effects
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of RA on human skin subjected to organ culture in the
presence or absence of c-erbB antagonists. In parallel, we have
examined the effects of these reagents on human epidermal
keratinocytes and dermal ®broblasts in monolayer culture. The
results strongly support a key role for HB-EGF acting directly
on c-erbB family members in keratinocytes in the genesis of
RA-induced epidermal hyperplasia.
MATERIALS AND METHODS
Human subjects All procedures involving human subjects were
approved by the University of Michigan Institutional Review Board, and
all subjects provided written informed consent.
Reagents Two inhibitors of c-erbB receptor tyrosine kinase (RTK)
activity were the generous gift of Drs W.L. Leopold and David Fry of
Figure 2. c-erbB-RTK antagonist inhibits
RA-induced hyperplasia in organ-cultured
human skin. Human skin was maintained in
organ culture for 8 d. At the end of the
incubation period, tissue was stained with
hematoxylin and eosin. Control skin
(KBM + Ca2+); skin treated with 3 mM RA; skin
treated with 3 mM RA and 1 mM PD169540;
quantitation of results. The number of
keratinocytes per unit length of epidermis was
assessed in hematoxylin and eosin stained sections
using NIH Image software. Values shown
represent means and standard errors based on
organ cultures from n = 5 different volunteers. *p
< 0.05 vs control; **p < 0.05 vs RA alone.
Scale bar: 100 mm.
Figure 1. Topical ROL and RA induce
epidermal thickening in human skin.
Volunteers were treated for 7 d with vehicle or
with 1.0% ROL under occlusion or 0.1% RA
under occlusion as described in Materials and
Methods. Biopsies were taken at the end of the
treatment period and stained with hematoxylin
and eosin or with an antibody to Ki-67. The
number of keratinocytes per unit length of
epidermis was assessed in hematoxylin and eosin
stained sections using NIH Image software. Values
shown represent means and standard errors based
on n = 17 separate volunteers for the vehicle and
ROL groups and n = 4 for the RA group. ***p
< 0.01 vs vehicle alone. Scale bar: 100 mm.
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P®zer Global Research and Development, Ann Arbor Laboratories, Ann
Arbor, MI. One of the compounds, PD158780, is a member of the 4-
anilinoquinazoline class of reversible inhibitors of c-erbB-RTK activity
(Fry et al, 1997; Rewcastle et al, 1998). The other compound,
PD169540, is an acrylamide-substituted 4-anilinopyrido[d]pyrimidine
designed to irreversibly alkylate Cys-773 within the ATP-binding pocket
of c-erbB1 and c-erbB2 (Smaill et al, 2000). A goat polyclonal antibody
to HB-EGF (cat. no. AF-259-NA) was obtained from R&D Systems
(Minneapolis, MN). The antibody neutralizes HB-EGF activity in Balb/
3T3 cell proliferation assays. According to the manufacturer's instruction,
the antibody does not cross react with any of a large number of growth
factors and cytokines, and does not neutralize either EGF or
amphiregulin. The lack of neutralizing activity against EGF was
con®rmed by us. Normal goat IgG was used as control. RA and ROL
were obtained from Sigma (St. Louis, MO). Stocks of RA were prepared
at 20 mg per ml in dimethyl sulfoxide (DMSO) and stored frozen,
protected from light. For in vitro assays, the RA stock was diluted in
culture medium at the time of use. At the highest concentration of RA
used (3 mM), the amount of DMSO in the culture medium was 0.05 ml
per ml of culture medium. This amount of DMSO had no measurable
effect on tissue structure or function (Varani et al, 1993d). A monoclonal
antibody to the proliferation-associated antigen Ki-67 was obtained from
Immunotech (Westbrook, ME).
Topical retinoid treatment of human skin Adult volunteers were
treated topically with RA, ROL, or vehicle on sun-protected buttock
skin sites. The vehicle consisted of seven parts 95% ethanol and three
parts propylene glycol (vol/vol). Subjects were treated for 3 d with 0.1%
RA or vehicle, or for 7 d with 1% ROL or vehicle. All treatments were
applied under plastic wrap occlusion and covered with an opaque
bandage to prevent drug loss and drug exposure to light. At the end of
the treatment period, replicate 2 mm full-thickness punch biopsies of
retinoid-treated and vehicle-treated skin were obtained from each
individual. Tissue was ®xed in 10% buffered formalin and examined
histologically after staining with hematoxylin and eosin. The number of
keratinocytes per unit length of epidermis was assessed morphometrically
using NIH Image software as previously described (Varani et al, 2000).
Additional tissue sections were stained with antibody to Ki-67 and the
number of positive cells was counted per unit length of epidermis. Ki-67
expression is associated with proliferation (Key et al, 1993).
Human skin organ cultures For the experiments shown in Figs 2
and 5, replicate 2 mm full-thickness punch biopsies of sun-protected hip
skin were obtained from volunteers. Immediately upon biopsy, the tissue
was immersed in culture medium consisting of Keratinocyte Basal
Medium (KBM) (Clonetics, Walkersville, MD). KBM is a low-Ca2+,
serum-free modi®cation of MCDB-153 medium optimized for high-
density keratinocyte growth (Wille et al, 1984). It was supplemented
with CaCl2 to bring the ®nal Ca
2+ concentration to 1.4 mM. After
transport to the laboratory on ice, the biopsies were incubated in a 96-
well dish containing 200 ml of Ca2+-supplemented KBM with or
without additional treatments. Cultures were incubated at 37°C in an
atmosphere of 95% air and 5% CO2. Incubation was for 8 d, with
change of medium containing the various treatments every 2 d. At the
end of the incubation period, tissue was ®xed in 10% buffered formalin
and examined histologically after staining with hematoxylin and eosin or
after staining with antibody to Ki-67. For the experiment shown in
Fig 4, human skin keratome biopsies were subjected to organ culture in
the presence or absence of 3 mM RA followed by RNA isolation and
northern blotting as previously described (Stoll and Elder, 1998), except
that the concentration of Ca2+ was adjusted to 0.1 mM or 1.4 mM by
the addition of CaCl2. cDNA insert probes for detection of HB-EGF
and 36B4 were prepared and labeled by random priming, as previously
described (Stoll and Elder, 1998).
Human epidermal keratinocytes and dermal ®broblasts in
monolayer culture Normal human epidermal keratinocytes were
obtained from skin biopsies and maintained in monolayer culture using
Keratinocyte Growth Medium (KGM; Clonetics). KGM contains the
same basal medium as KBM but is further supplemented with a mixture
of growth factors including 0.1 ng per ml EGF, 0.5 mg per ml insulin,
and 2% bovine pituitary extract. In some experiments, the HaCaT line
of immortalized human epidermal keratinocytes (Boukamp et al, 1988)
was used in place of normal keratinocytes. We (J.V., S.W.S., and J.T.E.,
unpublished observations) and others (Chaturvedi et al, 1999) have
observed that HaCaT cells grow well in KGM. Therefore, HaCaT cells
and normal human keratinocytes were propagated in exactly the same
manner. Fibroblasts obtained from human skin were grown in
monolayer culture using Dulbecco's modi®ed minimal essential medium
supplemented with nonessential amino acids and 10% fetal bovine serum
(DMEM-FBS). Both keratinocytes and ®broblasts were maintained at
37°C in an atmosphere of 95% air and 5% CO2. Cells were subcultured
by exposure to trypsin/ethylenediamine tetraacetic acid and used at
passage 2±3.
Proliferation and cytotoxicity assays For proliferation assays, cells
were initially plated at 4 3 104 cells per well of a 24-well dish in growth
medium (KGM for keratinocytes or DMEM-FBS for ®broblasts). After
allowing cells to attach for 1±2 h, the medium was removed and the
cells were washed twice in KBM (keratinocytes) or Ca2+-supplemented
KBM (®broblasts). The cells were then incubated for 48 h with or
without additional reagents as indicated in Results. At the end of the
incubation period, the cells were harvested by trypsinization and
enumerated using an automated particle counter (Coulter Electronics,
Hialeah, FL).
A 51Cr release assay was used to measure cytotoxic effects of the
irreversible c-erbB-RTK antagonist. For this assay, keratinocytes were
initially plated at 2 3 104 cells per well of a 24-well dish in growth
medium (KGM) and treated with 1 mCi per well of 51Cr. After allowing
cells to incorporate 51Cr for 1 d, the nonincorporated isotope was
removed and the cells were washed twice in KBM. The cells were then
incubated for 18 h with or without treatments as indicated in Results. At
the end of the incubation period, the percentage of incorporated 51Cr
that was released into the culture medium was determined. Our previous
studies have demonstrated the relationship between 51Cr release and
lethal injury in human epidermal keratinocytes (Varani et al, 1993c).
RESULTS
Induction of epidermal thickening in adult human skin by
topical retinoid treatment: comparison with hyperplasia
induced in organ-cultured human skin by RA As can be
seen in Fig 1, topical application of RA or ROL under occlusion
induced a marked increase in epidermal thickness, and in the
number of keratinocytes present per linear unit of epidermis. It can
also be seen that the number of Ki-67-positive cells increased
markedly, in parallel with skin thickening, in the retinoid-treated
groups.
Adult human skin was maintained in organ culture for 8 d in the
presence or absence of 3 mM RA. Figure 2 shows the typical
histologic appearance of organ-cultured tissue maintained in the
absence or presence of RA. In control medium (KBM containing
1.4 mM Ca2+ but no RA), the histologic appearance of the tissue
resembled that of freshly biopsied skin, as previously reported
(Varani et al, 1993b). Basal epithelial cells were mainly columnar in
shape, with orderly strati®cation of suprabasal keratinocytes
(Fig 2A). Scattered cells in the basal layer stained positive with
Figure 3. Irreversible and reversible c-erbB-RTK antagonists
inhibit proliferation of human epidermal keratinocytes in
monolayer culture. Keratinocytes were incubated for 2 d in KBM
alone or KBM supplemented with 0.5 mg per ml insulin and 2%
pituitary extract. Concomitantly the cells were treated with varying
concentrations of the two c-erbB-RTK antagonists. At the end of the
incubation period, cells were harvested and counted.
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antibody to the proliferation-associated antigen Ki-67, and occa-
sional mitoses were observed (data not shown). The appearance of
the RA-treated tissue was signi®cantly different. The epidermis was
thickened, due to an increase in the number of epidermal
keratinocytes. Basal and lower suprabasal cells demonstrated a
characteristic pallor on hematoxylin and eosin staining (Fig 2B).
The epidermis of RA-treated tissue was more disorganized than
that of controls, with loss of the normal progression from basal to
spinous to granular layers (Fig 2B). Loss of suprabasal keratinocyte
cohesion was frequently observed, leading to partial or complete
separation of the upper spinous layers in some RA-treated
specimens (data not shown). As was observed in retinoid-treated
skin in vivo (Fig 1), RA-treated cultures displayed a much larger
number of Ki-67-positive cells than did the controls, with Ki-67-
positive cells in the basal and ®rst suprabasal layers (not shown).
Effects of c-erbB-RTK antagonists on the ability of RA to
induce epidermal hyperplasia in organ-cultured
skin Figure 2C demonstrates the histologic appearance of
human skin after 8 d in organ culture in the presence of both
RA and the irreversible c-erbB-RTK antagonist, PD169540
(Smaill et al, 2000). It can be seen that PD169540 reversed the
effects of 3 mM RA at the concentration used (1 mM). It has
been established previously that this concentration of PD169540
is without effect on tyrosine kinases residing outside the c-erbB
family (Smaill et al, 2000). The histologic appearance of organ
cultures treated with RA + PD169540 was very similar to that
of control organ cultures not treated with either reagent. Both
the increase in epidermal thickness induced by RA and the
diminution of RA-stimulated epidermal thickness by PD169540
were statistically signi®cant, as demonstrated by keratinocyte
counts (Fig 2D). The effect of PD169540 was dose dependent:
0.5 mM and 0.1 mM PD169540 were also effective, albeit less
so than 1 mM, whereas lower concentrations had no effect (data
not shown). A reversible inhibitor of c-erbB-RTK activity,
PD158780 (Fry et al, 1997), was examined at 1 mM, 5 mM, and
10 mM for effects on RA-stimulated hyperplasia. Like
PD169540, this compound also reversed the effects of RA.
Antiproliferative activity was detected only at 5 and 10 mM
PD158780 (n = 3).
Effects of c-erbB-RTK antagonists on proliferation of
human epidermal keratinocytes in monolayer
culture The two c-erbB-RTK antagonists were examined for
their ability to inhibit the proliferation of human keratinocytes in
monolayer culture (Fig 3). Both reagents inhibited keratinocyte
growth in a concentration-dependent manner. There was a direct
relationship between effectiveness in inhibiting hyperplasia in organ
culture and effectiveness in blocking epithelial cell proliferation in
monolayer culture. PD169540 was clearly the more potent
compound in both assays. Additional studies showed that both
reagents were substantially more potent when the non-c-erbB
keratinocyte mitogens, insulin and bovine pituitary extract (Boyce
and Ham, 1983; Wille et al, 1984), were omitted from the
keratinocyte cultures (Fig 3). The concentration of PD169540 that
inhibited keratinocyte proliferation by 50% in the absence of
exogenous growth factors was approximately 0.008 mM, whereas
in the presence of insulin and pituitary extract it was 0.9 mM. In
spite of its growth-inhibitory capacity, PD169540 was essentially
nontoxic to keratinocytes at concentrations as high as 1.0 mM.
Essentially identical results were obtained with HaCaT cells as with
low passage keratinocytes (data not shown).
Retinoid stimulation of HB-EGF mRNA in organ culture is
intact under high-calcium conditions Whereas all of the
long-term organ culture studies presented here were carried out
under high-Ca2+ conditions (1.4 mM), previous demonstrations
that retinoids could potentiate HB-EGF expression in organ culture
were carried out under low (0.1 mM) Ca2+ conditions (Stoll and
Elder, 1998). In our previous studies we showed that elevation of
the calcium concentration in the culture medium to 1.4 mM
profoundly depressed the level of HB-EGF mRNA in organ
culture (Xia et al, 1997). To determine whether RA could induce
HB-EGF under high-Ca2+ conditions, organ cultures of adult
human skin were incubated for 8 h in basal medium containing
either 0.1 mM or 1.4 mM Ca2+, in the presence or absence of
3 mM RA (Fig 4). Consistent with previous results, HB-EGF
mRNA levels were strongly upregulated in low-Ca2+ medium (Xia
et al, 1997), and this induction was strongly potentiated by RA
(Stoll and Elder, 1998). Moreover, HB-EGF induction was
markedly diminished by elevation of the medium Ca2+ to
1.4 mM (Xia et al, 1997). In the presence of both high Ca2+ and
RA, the stimulatory effect of 3 mM RA was clearly dominant over
the inhibitory effect of 1.4 mM Ca2+, demonstrating that RA can
induce HB-EGF under the calcium concentration required for
long-term maintenance of organ cultures.
Effects of neutralizing anti-HB-EGF on RA-induced
epidermal hyperplasia in organ-cultured skin Organ
cultures of adult human skin were treated for 8 d with 3 mM RA
and concomitantly with 10 mg per ml of either a neutralizing
antibody to HB-EGF or normal goat serum. Fresh culture medium
and reagents were added at 2 d intervals. At the end of the
incubation period, the tissue was examined histologically. In the
presence of antibody to HB-EGF, RA-stimulated hyperplasia was
consistently inhibited (Fig 5). Again, the response was dose
dependent: 5 mg per ml anti-HB-EGF also inhibited RA-induced
changes, albeit less effectively than 10 mg per ml. Concentrations
lower than 5 mg per ml had no detectable effect (data not shown).
Effects of c-erbB-RTK antagonists and antibody to HB-
EGF on RA-induced survival and proliferation of human
dermal ®broblasts Human dermal ®broblasts were harvested
from monolayer culture and plated in DMEM-FBS. After allowing
the cells to attach for 2 h in this culture medium, the cells were
washed and propagated for 48 h in KBM containing 0.15 mM
CaCl2 (low Ca
2+), with or without 3 mM RA. At the end of the
incubation period, the cells remaining in the wells were harvested
and counted. When incubated under low-Ca2+ conditions, 80%±
90% of the ®broblasts died over the 48 h period and the number of
viable cells remaining was correspondingly reduced (Fig 6).
Consistent with previous reports (Varani et al, 1990a; 1990b),
Figure 4. RA induction of HB-EGF mRNA overcomes high-
Ca2+-induced suppression in human skin organ culture. Organ
cultures of human skin were incubated for 8 h in KBM containing either
0.1 or 1.4 mM Ca2+ in the presence or absence of 3 mM RA as
indicated above the autoradiograms. RNAs were isolated and northern
blots were prepared and hybridized with HB-EGF or 36B4 probes as
described in Materials and Methods.
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RA markedly and signi®cantly promoted ®broblast survival under
these low-Ca2+ conditions. The number of cells recovered was
virtually the same as the number added to the wells originally
(Fig 6). As can be seen from the ®gure, there was no inhibition of
RA-stimulated ®broblast survival by the c-erbB-RTK inhibitors or
by anti-HB-EGF antibody under these conditions (Fig 6).
DISCUSSION
Recent studies from our laboratory have suggested that retinoid-
induced keratinocyte growth in monolayer culture and retinoid-
induced skin hyperplasia are mediated at least in part by induction
of HB-EGF (Stoll and Elder, 1998). Here we present direct
evidence to support this hypothesis. Speci®cally, it is shown that
two different c-erbB-RTK antagonists and a neutralizing antibody
to HB-EGF prevented RA-induced skin hyperplasia in organ-
cultured human skin. There was a direct relationship between
inhibition of keratinocyte proliferation in monolayer culture and
prevention of skin hyperplasia, in that the irreversible inhibitor was
substantially more potent in both assays. These results are likely to
be pertinent to the in vivo situation. Topical application of either
RA or ROL produced a robust epidermal hyperplasia characterized
by a marked increase in Ki-67 positivity, indicative of entry of basal
keratinocytes into the cell cycle (Fig 1). The process of organ
culture did lead to a slight increase in Ki-67 positivity, as compared
to freshly biopsied normal or vehicle-treated skin. Retinoid
treatment induced a marked increase over this baseline, however.
The relationship between retinoid action and c-erbB function in
epidermal hyperplasia is not fully understood. At least three
possibilities exist. First, retinoids and c-erbB ligands may each
induce their own separate signals that are both required for
hyperplasia. Second, retinoids may directly activate c-erbB
receptors in a ligand-independent manner, similar to the activation
produced by ultraviolet light or hydrogen peroxide (Gamou and
Shimizu, 1995; Tyrrell, 1996; Peus et al, 1999). A retinoid effect on
c-erbB function would not be totally unexpected. Retinoids can
intercalate into cell membranes and function as mild detergents at
high concentrations (Meeks et al, 1981). Consistent with this
hypothesis, we have shown that micromolar concentrations of RA
are required to induce HB-EGF mRNA in keratinocytes, whereas
interleukin 1b mRNA is induced at subnanomolar concentrations
(Elder et al, 1991; Stoll and Elder, 1998). Detergent-like activity
probably does not account for the entire retinoid effect, however.
In a past study, we showed that the ionic detergent sodium dodecyl
sulfate could stimulate keratinocyte proliferation in monolayer
culture but could not induce hyperplasia in organ-cultured skin
(Varani et al, 1991; 1993a). Moreover, Xiao and colleagues found
that retinoid-induced skin hyperplasia and expression of HB-EGF
were both inhibited in mouse skin engineered to express a
dominant negative retinoic acid receptor (RAR) in suprabasal
keratinocytes (Xiao et al, 1999). This ®nding indicates that retinoid-
induced epidermal hyperplasia requires RAR function. RAR
function is known to be in¯uenced by RAR tyrosine phosphoryl-
ation, suggesting a point of convergence for c-erbB and RAR
signaling (Rochette-Egly et al, 1992).
A third possibility involves retinoid induction of c-erbB
expression and/or elaboration of c-erbB ligands. Previous studies
from our laboratory (Stoll and Elder, 1998) support such a
possibility. Speci®cally, it was shown in two different models (i.e.,
human skin organ culture and intact mouse skin) that retinoid
treatment induces upregulation of HB-EGF mRNA but has no
major effect on two other epidermal-derived c-erbB ligands (i.e.,
amphiregulin and TGF-a). The ability of an antibody to HB-EGF
to reduce the hyperplastic response induced by retinoid treatment
(this study) demonstrates for the ®rst time that retinoid-stimulated
HB-EGF production is, at least in part, responsible for retinoid-
induced hyperplasia in human skin.
It has long been recognized that development of the skin and its
appendages requires multiple signals to pass between epidermis and
Figure 5. Antibody to HB-EGF inhibits RA-induced hyperplasia in organ-cultured human skin. Human skin was maintained in organ
culture for 8 d. At the end of the incubation period, tissue was stained with hematoxylin and eosin. Control skin (KBM + Ca2+); skin treated with
3 mM RA; skin treated with 3 mM RA and 10 mg per ml anti-HB-EGF. Quantitation of results. The number of keratinocytes per unit length of
epidermis was assessed in hematoxylin and eosin stained sections using NIH Image software. Values shown represent means and standard errors based
on organ cultures from n = 3 different volunteers. Normal goat IgG (10 mg per ml) was ineffective. *p < 0.05 vs control; **p < 0.05 vs RA alone.
Scale bar: 100 mm.
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dermis, and that these signals are profoundly in¯uenced by retinoids
(Hardy, 1989; Covant and Hardy, 1990; Ross et al, 2000). It is
perhaps less well appreciated that epithelial±mesenchymal inter-
actions are also important for ongoing homeostasis of mature
epidermis and other epithelia. For example, when the dermis and
epidermis of mature skin are separated and cultured in isolation, the
dermis remains viable but the epidermis rapidly dies (Varani et al,
1994). We have shown that survival of organ-cultured human skin
requires a medium Ca2+ concentration that is optimal for ®broblast
growth (e.g., 1.4 mM) rather than for growth of keratinocytes
(e.g., 0.1 mM). Interestingly, the addition of RA to low-Ca2+
cultures prevents epidermal degeneration, preserving epithelial
viability for up to 12 d (Varani et al, 1993b). It is attractive to
hypothesize that RA-induced survival of skin in organ culture
under low-Ca2+ conditions is mediated by effects on dermal
elements as RA preserves ®broblast viability and promotes growth
of these cells under the same low-Ca2+ conditions that preserve
organ-cultured skin (Varani et al, 1990a; 1990b). Taken together
with these past observations, our ®ndings suggest that whereas a
viable dermis may be required for preservation of epidermal
structure, and whereas retinoid effects on dermal cells may be
required for preservation of organ-cultured skin under low-Ca2+
conditions, the hyperproliferative effects of retinoids are exerted
directly upon keratinocytes, at least in part, via the action of HB-
EGF on c-erbB receptors.
How retinoids promote ®broblast survival under low-Ca2+
conditions is not fully understood. In our studies, we found that the
effects of RA on dermal ®broblasts were not blocked by inhibitors
of c-erbB-RTK activity or by a neutralizing antibody against HB-
EGF. This ®nding stands in marked contrast to the pronounced
effects of these reagents on cultured keratinocytes. As an alternative
hypothesis, we suggest a direct retinoid effect on Ca2+ transport
across the ®broblast plasma membrane. In a previous study, we
demonstrated that, when ®broblasts that had been incubated in a
medium containing 1.4 mM extracellular Ca2+ were suddenly
shifted to a low-Ca2+ environment, the intracellular Ca2+
concentration fell precipitously (Varani et al, 1995). In contrast,
®broblasts treated with RA maintained intracellular Ca2+ concen-
trations in spite of the reduction in extracellular Ca2+. The capacity
to maintain suf®cient intracellular Ca2+ is essential to ®broblast
survival and growth. How retinoids act to preserve intracellular
Ca2+ in ®broblasts is, itself, not fully understood. In part this may
re¯ect a direct membrane effect. This is unlikely to be the complete
story, however, as retinoids that do not activate RAR neither
prevent the loss of Ca2+ from ®broblasts when the cells are
incubated under low-Ca2+ conditions nor preserve cell viability
under the same conditions (Varani et al, 1995).
Clearly, whereas dermal and epidermal elements are present both
in living skin in vivo and in organ culture ex vivo, these two settings
differ in several important ways. Therefore, it is important to ask
whether the molecular events causing retinoid hyperplasia in
organ-cultured skin are the same as those producing retinoid
hyperplasia in intact skin. Whereas in vitro models can never fully
replicate what occurs in vivo, it is of interest to note that retinoid
preparations that induce keratinocyte proliferation and epidermal
thickening in vivo (0.025%±0.1% RA) produce drug concentrations
of 1±3 mM in the viable portion of the epidermis (Duell et al,
1992). This is the same concentration range that is effective in
organ culture (Stoll and Elder, 1998, and this report), but it is 10±
100-fold higher than the concentration required for activation of
retinoid receptors in vitro (Duell et al, 1992), or to activate other
keratinocyte retinoid responses such as induction of interleukin 1b
(Stoll and Elder, 1998). Also, as Ca2+ concentrations are on the
order of 1.4 mM in the extracellular ¯uid in vivo (Grzesiak and
Pierschbacher, 1995), the data presented in Fig 4 and elsewhere
(Stoll and Elder, 1998) strongly suggest that retinoids are able to
overcome the effects of high calcium to induce HB-EGF after
topical application in vivo as well as in organ culture. Taken
together, these characteristics suggest that the hyperplastic response
to retinoids proceeds via the same mechanism in organ culture and
intact skin.
Fibroblasts are the major cellular source of collagen production
in the skin. Increased collagen production and reduced collagen
degeneration are thought to be responsible for the antagonistic
effect of topical retinoids on photoaging (Fisher et al, 2000).
Likewise, induction of new collagen elaboration may underlie the
bene®cial effects of topical retinoids in natural-aged skin (Varani et
al, 2000). In spite of these bene®cial effects, topical retinoids can
induce undesirable effects such as scaling and redness in some
people (Fisher et al, 1991). We found that c-erbB signaling appears
to play little if any role in the effect of RA on ®broblasts. Our
®ndings therefore suggest that it may be possible to dissociate the
clinically undesirable effects of retinoids on epidermal keratinocytes
from their desirable effects on dermal collagen biosynthesis and
degradation.
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Figure 6. c-erbB RTK antagonists and antibody to HB-EGF do
not interfere with the ability of RA to induce ®broblast survival
and growth under low-Ca2+ conditions in monolayer culture.
Fibroblasts were incubated for 2 d in KBM with or without varying
concentrations of the two c-erbB-RTK antagonists or anti-HB-EGF
monoclonal antibody. At the end of the incubation period, cells were
harvested and counted.
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